成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)-

Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)- Struktur
912569-37-0
CAS-Nr.
912569-37-0
Englisch Name:
Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)-
Synonyma:
Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)-
CBNumber:
CB88336978
Summenformel:
C16H24O4
Molgewicht:
280.36
MOL-Datei:
912569-37-0.mol

Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)- Eigenschaften

Siedepunkt:
383.7±37.0 °C(Predicted)
Dichte
1.17±0.1 g/cm3(Predicted)
pka
14.65±0.10(Predicted)

Sicherheit

Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)- Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Fumarrano is an angiogenesis inhibitors. It also interacts with P. falciparum methionine aminopeptidase 2 to inhibit malaria parasite growth in vitro and in vivo

Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)- Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)- Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 1)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
TargetMol Chemicals Inc. 15002134094
marketing@targetmol.cn China 19704 58

  • Bicyclo[3.1.0]hexan-2-one, 5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (1S,5S,6S)-
  • 912569-37-0
Copyright 2019 ? ChemicalBook. All rights reserved